Showing 1 - 10 of 11 Alzheimer%27s Disease
18F-MK-6240 Tau PET and Brain Inflammation in Alzheimer’s Disease

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verif ... Read more >

A Phase IIa randomized, double-blind, placebo-controlled study of the effects of L-serine on Mild Cognitive Impairment (MCI)

Status: Enrolling

Investigator: Gustavo Roman

Study Coordinator: Edwin Vega Vargas

Phone: 713.443.2044

This is a Phase IIa, randomized, double-blinded, placebo-controlled trial to determine the tolerability of L-serine for Mild Cognitive Impairment patients and assess preliminary indications of efficacy. Efficacy will be assessed by cognitive tes ... Read more >

A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6955

The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Status: Enrolling

Investigator: Juan Toledo Atucha

Study Coordinator: Maushami Gurung

Phone: 346.238.1565

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administere ... Read more >

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Status: Enrolling

Investigator: Juan Toledo Atucha

Study Coordinator: Quang Bobby Nguyen

Phone: 832.530.2622

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine w ... Read more >

Glutathione and Alzheimer's Disease

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Chimaoge Onyechi

Phone: 713.363.7729

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigat ... Read more >

Glutathione in Mild Cognitive Impairment

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Chimaoge Onyechi

Phone: 713.363.7729

Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mech ... Read more >

Houston Alzheimer Disease Study

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Andrea Franco Pando

Phone: 713.441.1150

The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abiliti ... Read more >

Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS)

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Jeffrey Ling

Phone: 713.363.7753

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, ... Read more >

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Chimaoge Onyechi

Phone: 713.363.7729

New IDEAS is an observational, open-label, longitudinal cohort study designed to address the requirements of the CED provisions of the NCD on beta-amyloid PET. Building on the initial Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, ... Read more >

Role of Brain Inflammation in Alzheimer’s Disease

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is ... Read more >